The AstraZeneca (AZN) Phase III Arimidex study began in 2001 and proceeded to evaluate 208 postmenopausal women in 22 countries. The results were presented on Thursday at the 2006 San Antonio Breast Cancer Symposium (SABCS), in North America.
The study reports, postmenopausal women with advanced breast cancer, who received Astrazeneca PLC's ARIMIDEX (anastrozole) in combination with Genentech Inc's Herceptin (trastuzumab) showed a significant improvement in progression-free survival.
The results of the study indicate that the drug ARIMIDEX, in combination with Herceptin, improves the efficacy of breast cancer treatment.
The organizers reported that the overall median survival for patients receiving ARIMIDEX with Herceptin was 28.5 months which is an extended median progression-free survival of 4.8 months, 2.4 months longer than those receiving Arimidex alone.